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ACE Research Vignette: Startups lead the way in creating a 
nanobiotechnology industry 
 
This series of research vignettes is aimed at sharing current and interesting research findings from our team of 
international Entrepreneurship researchers. In this vignette, Dr Martin Bliemel and his research team explore the 
emergence and evolution of a new knowledge intensive industry, i.e. the nanobiotechnology industry.  
 
Background and Research Question 
 
Industries generally emerge and evolve over time in known patterns. At first there is a fluid phase with a lot of uncertainty 
about the direction and segmentation of the overall industry. This is followed by a transitional phase and a specific phase. 
Over time, the emphasis usually shifts from product innovation to process innovation, and more clearly defined 
segmentation of the market.  
 
However, new entrants into a new industry are not necessarily all new firms (aka de novo firms). Multinational firms often 
have some expertise outside their core areas and can be the first to be in an industry. However, for historical reasons, 
they may under-resource the new area and fail to out-innovate more nimble smaller firms that enter the industry. In 
many cases, the firms entering the industry are specifically designed to be in the new industry, and do not carry any of the 
organizational baggage of their competitors. Figure 1 illustrates the cumulative count of firms in the nanobiotechnology 
industry according to whether the firms were multinational corporations, startups (de novo), or smaller incumbents (de 
alio) who transitioned into the industry from a related area after at least three years in that other area. The figure also 
reflects the number of exits from the industry, where exits may include closure or trade sale to another firm. 
 
FIGURE 1. Factors influencing the sales growth <–> employment growth relationship   
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How we investigated this 
 
We followed the emergence of this industry at three different intervals (2005, 2008 and 2011), at which we queried 
multiple datasets in biotechnology to see which firms entered the industry. For each firm across the three datasets, we 
could then check firm characteristics (e.g., size, geography, subsector), when they entered the industry, and whether they 
exited the industry. We tested for when each firm developed nano- and bio-technology capabilities by searching each 
firms’ website, press releases, publications, and US patents. Patents were identified as ‘nano’ and ‘bio’ based on 
previously published criteria. 
 
What we found 
 
While large multinational firms may be some of the first firms in the industry, they are not necessarily able to lock out 
new entrants and can even face considerable disadvantages to smaller startups when it comes to integrating multiple 
areas of knowledge. Larger multinational firms face a challenge of breaking down ‘silos’ of knowledge in order to 
participate more actively in industries that are based on a combination of multiple knowledge areas. Even if they do 
manage to integrate some of their knowledge across these silos, this new integrated knowledge is overshadowed by their 
existing capabilities. Instead, it is the smaller firms who are able to focus specifically on this integrate knowledge and can 
use patents as a way to stake their territory, possibly leading to radical innovation and economic growth. While our 
findings are specific to the nanobiotechnology industry, our findings reinforce similar findings in other studies that reveal 
how multinationals often struggle to integrate other areas of knowledge related to other industries.  
 
Business and Policy Advice 
 
Startups (and larger firms) interested in commercializing technologies based on multiple areas of knowledge would be 
wise to co-locate with complementary firms or research organizations. Facilitating such colocation, in turn, has clear 
implications for university technology transfer policy and regional economic policy if the economic potential is to benefit 
the region. Universities may consider enabling star scientists to launch their startups on campus, without the researchers 
having to interrupt their academic career. Such exchanges of knowledge due to co-location are also known as ‘spill-overs’. 
Nearby science parks are another means of enabling spill-overs between universities, industry and also across disparate 
technological fields. Here, too, startups have an advantage of being more mobile regarding their location and proximity to 
complementary organizations. Keeping startups in the region (e.g., with tax breaks for science park residents) may pay off 
for the region in terms of subsequent job creation, and may be much easier than trying to persuade larger firm to relocate 
into the region. 
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